960 / 1674
Randomized Trial of Accelerated Partial Breast Irradiation,
The RAPID trial
Olivotto et al, JCO 2013
Primary endpoint: IBTR, assumed 1.5% at 5 yr with WBI
Secondary endpoints: adverse cosmesis, RT toxicity, QoL, DFS, event-free
survival, OS
Study design: non-inferiority, accept up to max 1.5% increase in IBTR at 5 yr,
interim planned at 30 and 50 IBTR, not reached
This report is data
from a pre-
planned interim
analysis of global
cosmetic score